CStone Pharmaceuticals

DB:PH4 Stock Report

Market Cap: €785.5m

CStone Pharmaceuticals Management

Management criteria checks 3/4

CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 3.83 years. total yearly compensation is CN¥23.73M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth €9.95M. The average tenure of the management team and the board of directors is 3.4 years and 4.7 years respectively.

Key information

Jason Yang

Chief executive officer

CN¥23.7m

Total compensation

CEO salary percentage20.19%
CEO tenure3.8yrs
CEO ownership1.3%
Management average tenure3.4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Yang's remuneration changed compared to CStone Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CN¥24mCN¥5m

-CN¥437m

Sep 30 2025n/an/a

-CN¥407m

Jun 30 2025n/an/a

-CN¥377m

Mar 31 2025n/an/a

-CN¥234m

Dec 31 2024CN¥29mCN¥5m

-CN¥91m

Sep 30 2024n/an/a

-CN¥117m

Jun 30 2024n/an/a

-CN¥142m

Mar 31 2024n/an/a

-CN¥255m

Dec 31 2023CN¥58mCN¥5m

-CN¥367m

Sep 30 2023n/an/a

-CN¥559m

Jun 30 2023n/an/a

-CN¥750m

Mar 31 2023n/an/a

-CN¥827m

Dec 31 2022CN¥62mCN¥3m

-CN¥903m

Compensation vs Market: Jason's total compensation ($USD3.50M) is above average for companies of similar size in the German market ($USD1.11M).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Yang (62 yo)

3.8yrs
Tenure
CN¥23,726,000
Compensation

Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...

Leadership Team

NamePositionTenureCompensationOwnership
Jianxin Yang
CEO, President of R&D and Executive Director3.8yrsCN¥23.73m1.27%
€ 10.0m
Weicong Ni
CFO & Company Secretary3.4yrsno datano data
Ying Hua Zhang
Senior VP & Chief Operating Officer2.4yrsno datano data
Michael J. Choi
Chief Business & Strategy Officer5.1yrsno datano data
Yujuan La
Senior Vice President of Product Development5.1yrsno datano data
Qingmei Shi
Senior VP & Chief Medical Officer2.4yrsno datano data
Qinzhou Qi
VP and Head of R&D Management & Chief of Staff to the CEOless than a yearno datano data
3.4yrs
Average Tenure
48yo
Average Age

Experienced Management: PH4's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jianxin Yang
CEO, President of R&D and Executive Directorno dataCN¥23.73m1.27%
€ 10.0m
Paul A. Bunn
Member of Scientific Advisory Board7.3yrsno datano data
Zhengguo Hu
Non-Executive Director4.9yrsCN¥341.00k0.12%
€ 958.5k
Fang Xie
Independent Non-Executive Directorless than a yearCN¥86.00k0.00053%
€ 4.2k
Kenneth Howard Jarrett
Independent Non-Executive Directorless than a yearCN¥93.00kno data
Kenneth Walton Hitchner
Non Executive Director4.5yrsCN¥315.00k0.13%
€ 1.0m
Weiping Zou
Member of Scientific Advisory Board7yrsno datano data
Wei Li
Non-Executive Chairman10.5yrsCN¥341.00k0.061%
€ 481.3k
Catherine Yen
Independent Non-Executive Directorless than a yearno datano data
4.7yrs
Average Tenure
63yo
Average Age

Experienced Board: PH4's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 04:48
End of Day Share Price 2026/06/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CStone Pharmaceuticals is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
null nullGuoyuan Securities (HK) Ltd
Hanyang HuangIndustrial Securities Co. Ltd.